NCT06963177

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.

Conditions

• Endometriosis-related Pain

Interventions

Type	Name	Description
DRUG	GenSci048	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2025-05-26
• Primary completion: 2028-05-15
• Completion: 2030-01-06
• First posted: 2025-05-08
• Last updated: 2025-08-12

Locations

1 site across 1 country: China